JP2021501138A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021501138A5 JP2021501138A5 JP2020522288A JP2020522288A JP2021501138A5 JP 2021501138 A5 JP2021501138 A5 JP 2021501138A5 JP 2020522288 A JP2020522288 A JP 2020522288A JP 2020522288 A JP2020522288 A JP 2020522288A JP 2021501138 A5 JP2021501138 A5 JP 2021501138A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- ischemia
- use according
- antibody fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 21
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 21
- 208000028867 ischemia Diseases 0.000 claims 10
- 230000000302 ischemic effect Effects 0.000 claims 10
- 150000001413 amino acids Chemical class 0.000 claims 8
- 239000003795 chemical substances by application Substances 0.000 claims 7
- 238000001356 surgical procedure Methods 0.000 claims 7
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 6
- 208000007536 Thrombosis Diseases 0.000 claims 5
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims 4
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 239000003146 anticoagulant agent Substances 0.000 claims 3
- 229940127219 anticoagulant drug Drugs 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 208000014674 injury Diseases 0.000 claims 3
- 150000003904 phospholipids Chemical class 0.000 claims 3
- 229960000187 tissue plasminogen activator Drugs 0.000 claims 3
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 2
- 208000005189 Embolism Diseases 0.000 claims 2
- 206010064571 Gene mutation Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 206010063837 Reperfusion injury Diseases 0.000 claims 2
- 208000027418 Wounds and injury Diseases 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- 208000031225 myocardial ischemia Diseases 0.000 claims 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims 2
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 claims 1
- VXIXUWQIVKSKSA-UHFFFAOYSA-N 4-hydroxycoumarin Chemical class C1=CC=CC2=C1OC(=O)C=C2O VXIXUWQIVKSKSA-UHFFFAOYSA-N 0.000 claims 1
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 206010051055 Deep vein thrombosis Diseases 0.000 claims 1
- 206010056340 Diabetic ulcer Diseases 0.000 claims 1
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 1
- 206010015150 Erythema Diseases 0.000 claims 1
- 229940123457 Free radical scavenger Drugs 0.000 claims 1
- 208000010496 Heart Arrest Diseases 0.000 claims 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 1
- 206010056328 Hepatic ischaemia Diseases 0.000 claims 1
- 208000033892 Hyperhomocysteinemia Diseases 0.000 claims 1
- 206010021113 Hypothermia Diseases 0.000 claims 1
- 206010022680 Intestinal ischaemia Diseases 0.000 claims 1
- 206010028851 Necrosis Diseases 0.000 claims 1
- 208000008348 Post-Concussion Syndrome Diseases 0.000 claims 1
- 201000005660 Protein C Deficiency Diseases 0.000 claims 1
- 206010051292 Protein S Deficiency Diseases 0.000 claims 1
- 108010094028 Prothrombin Proteins 0.000 claims 1
- 102100027378 Prothrombin Human genes 0.000 claims 1
- 208000010378 Pulmonary Embolism Diseases 0.000 claims 1
- 206010063897 Renal ischaemia Diseases 0.000 claims 1
- 108010023197 Streptokinase Proteins 0.000 claims 1
- 208000001435 Thromboembolism Diseases 0.000 claims 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims 1
- 206010047249 Venous thrombosis Diseases 0.000 claims 1
- 229960002054 acenocoumarol Drugs 0.000 claims 1
- VABCILAOYCMVPS-UHFFFAOYSA-N acenocoumarol Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=C([N+]([O-])=O)C=C1 VABCILAOYCMVPS-UHFFFAOYSA-N 0.000 claims 1
- 229960003318 alteplase Drugs 0.000 claims 1
- 229940127218 antiplatelet drug Drugs 0.000 claims 1
- 239000003698 antivitamin K Substances 0.000 claims 1
- KXNPVXPOPUZYGB-XYVMCAHJSA-N argatroban Chemical compound OC(=O)[C@H]1C[C@H](C)CCN1C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C1=CC=CC2=C1NC[C@H](C)C2 KXNPVXPOPUZYGB-XYVMCAHJSA-N 0.000 claims 1
- 229960003856 argatroban Drugs 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 230000006041 cell recruitment Effects 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 239000000701 coagulant Substances 0.000 claims 1
- 230000024203 complement activation Effects 0.000 claims 1
- 230000008602 contraction Effects 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 231100000321 erythema Toxicity 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 108010091897 factor V Leiden Proteins 0.000 claims 1
- 229960002897 heparin Drugs 0.000 claims 1
- 229920000669 heparin Polymers 0.000 claims 1
- 208000013746 hereditary thrombophilia due to congenital protein C deficiency Diseases 0.000 claims 1
- 230000003225 hyperhomocysteinemia Effects 0.000 claims 1
- 230000002631 hypothermal effect Effects 0.000 claims 1
- 201000001881 impotence Diseases 0.000 claims 1
- 210000004969 inflammatory cell Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 230000000938 luteal effect Effects 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 229960004127 naloxone Drugs 0.000 claims 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 claims 1
- 230000017074 necrotic cell death Effects 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 239000004090 neuroprotective agent Substances 0.000 claims 1
- 229960000715 nimodipine Drugs 0.000 claims 1
- 230000003647 oxidation Effects 0.000 claims 1
- 238000007254 oxidation reaction Methods 0.000 claims 1
- 210000003899 penis Anatomy 0.000 claims 1
- 230000002085 persistent effect Effects 0.000 claims 1
- 230000004962 physiological condition Effects 0.000 claims 1
- 229940039716 prothrombin Drugs 0.000 claims 1
- 239000002516 radical scavenger Substances 0.000 claims 1
- 230000010410 reperfusion Effects 0.000 claims 1
- 229960002917 reteplase Drugs 0.000 claims 1
- 108010051412 reteplase Proteins 0.000 claims 1
- 229960005202 streptokinase Drugs 0.000 claims 1
- 230000000451 tissue damage Effects 0.000 claims 1
- 231100000827 tissue damage Toxicity 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 229960005356 urokinase Drugs 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 229940019333 vitamin k antagonists Drugs 0.000 claims 1
- 229960005080 warfarin Drugs 0.000 claims 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762577543P | 2017-10-26 | 2017-10-26 | |
| US62/577,543 | 2017-10-26 | ||
| PCT/US2018/057793 WO2019084460A1 (en) | 2017-10-26 | 2018-10-26 | INHIBITION OF OXIDATION-SPECIFIC EPITOPES TO TREAT ISCHEMIC REPERFUSION INJURY |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021501138A JP2021501138A (ja) | 2021-01-14 |
| JP2021501138A5 true JP2021501138A5 (enExample) | 2021-12-02 |
| JP7403164B2 JP7403164B2 (ja) | 2023-12-22 |
Family
ID=66247717
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020522288A Active JP7403164B2 (ja) | 2017-10-26 | 2018-10-26 | 虚血性再灌流障害を治療するための酸化特異的エピトープの阻害 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US11897969B2 (enExample) |
| EP (1) | EP3700567A4 (enExample) |
| JP (1) | JP7403164B2 (enExample) |
| WO (1) | WO2019084460A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019148204A1 (en) * | 2018-01-29 | 2019-08-01 | The Regents Of The University Of California | Therapies and methods to treat tlr2-mediated diseases and disorders |
| WO2024194686A2 (en) * | 2023-03-17 | 2024-09-26 | Oxitope Pharma B.V. | Anti-phosphocholine antibodies and methods of use thereof |
| WO2024194685A2 (en) * | 2023-03-17 | 2024-09-26 | Oxitope Pharma B.V. | Anti-phosphocholine antibodies and methods of use thereof |
| CN116500280B (zh) * | 2023-06-26 | 2023-09-12 | 中国医学科学院北京协和医院 | 一组诊断颈动脉体瘤的标志物及其应用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| EP0604580A1 (en) | 1991-09-19 | 1994-07-06 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES |
| DE69233528T2 (de) | 1991-11-25 | 2006-03-16 | Enzon, Inc. | Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen |
| US5639635A (en) | 1994-11-03 | 1997-06-17 | Genentech, Inc. | Process for bacterial production of polypeptides |
| CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP1972194A1 (en) | 1996-12-03 | 2008-09-24 | Amgen Fremont Inc. | Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom |
| US6271199B2 (en) * | 1997-02-15 | 2001-08-07 | Millennium Pharmaceuticals, Inc. | Treatment of infarcts |
| US6225070B1 (en) | 1997-08-07 | 2001-05-01 | The Regents Of The University Of California | Antibodies to oxidation-specific epitopes on lipoprotein and methods for their use in detecting, monitoring and inhibiting the growth of atheroma |
| WO1999029888A1 (en) | 1997-12-05 | 1999-06-17 | The Scripps Research Institute | Humanization of murine antibody |
| US20090130776A1 (en) * | 2005-09-01 | 2009-05-21 | Canon Kabushiki Kaisha | Binding protein molecule |
| AU2008285626B2 (en) * | 2007-08-03 | 2013-09-12 | Neuramedy Co., Ltd. | Use of TLR-2 antagonists for treatment of reperfusion injury and tissue damage |
| US8652476B2 (en) * | 2009-07-27 | 2014-02-18 | Niigata University | Pharmaceutical composition for treating ischemic events |
| WO2014113510A1 (en) * | 2013-01-15 | 2014-07-24 | Xencor, Inc. | Rapid clearance of antigen complexes using novel antibodies |
| WO2014131034A2 (en) * | 2013-02-25 | 2014-08-28 | The Regents Of The University Of California | Antibodies to oxidized phospholipids |
-
2018
- 2018-10-26 US US16/759,331 patent/US11897969B2/en active Active
- 2018-10-26 JP JP2020522288A patent/JP7403164B2/ja active Active
- 2018-10-26 EP EP18869918.5A patent/EP3700567A4/en active Pending
- 2018-10-26 WO PCT/US2018/057793 patent/WO2019084460A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12371481B2 (en) | Methods for treating age-related macular degeneration | |
| Dinarello et al. | Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases | |
| Kovacs et al. | Angiogenic and inflammatory vitreous biomarkers associated with increasing levels of retinal ischemia | |
| Stewart | The expanding role of vascular endothelial growth factor inhibitors in ophthalmology | |
| Shimokawa et al. | Chronic treatment with interleukin-1 beta induces coronary intimal lesions and vasospastic responses in pigs in vivo. The role of platelet-derived growth factor. | |
| Kimoto et al. | Anti‐VEGF agents for ocular angiogenesis and vascular permeability | |
| JP6460993B2 (ja) | 血管疾患及びその合併症の処置 | |
| BRPI0611765A2 (pt) | anticorpos estáveis e solúveis que inibem tnfalfa | |
| JP2019510078A5 (enExample) | ||
| JP2019510078A (ja) | Ｉｌ−６アンタゴニスト製剤およびその使用 | |
| JP2017535285A5 (enExample) | ||
| JP2016501273A (ja) | Ｂｍｐ−６抗体 | |
| JP2020510627A (ja) | 脂肪肝を予防および治療するための方法 | |
| FI3852617T3 (fi) | Vasta-ainefragmenttien käyttö tikagrelorin aktiivisuuden kääntämiseen | |
| JP2022501368A5 (enExample) | ||
| IL293367A (en) | Pharmaceutical formulations and dosage regimens for antibodies to factor xi/xia | |
| Roubille et al. | What is the role of erythropoietin in acute myocardial infarct? Bridging the gap between experimental models and clinical trials | |
| US20110212900A1 (en) | Method for prophylactic and/or therapeutic treatment of pain associated with hematopoietic cell transplantation | |
| JP2023531315A5 (enExample) | ||
| JP7574079B2 (ja) | 小児患者における癌の治療のためのラムシルマブ | |
| JP6431552B2 (ja) | Ｔａｆｉおよびｐａｉ−１の二重標的化 | |
| Dubey et al. | Vascular Endothelial Growth Factors: Pharmacological aspects and applications in ophthalmic practices | |
| JP2009539757A (ja) | 血栓溶解活性を有するａｄａｍｔｓ１３含有組成物 |